Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $753,725.00 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total value of $753,725.00. Following the sale, the chief executive officer now owns 85,942 shares in the company, valued at approximately $3,701,521.94. The trade was a 16.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.94, for a total value of $821,450.00.
• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The stock was sold at an average price of $40.39, for a total transaction of $782,556.25.
• On Wednesday, October 9th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The stock was sold at an average price of $38.24, for a total transaction of $597,500.00.
• On Wednesday, September 25th, Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock. The shares were sold at an average price of $46.05, for a total value of $1,064,906.25.

Vera Therapeutics Price Performance

Vera Therapeutics stock opened at $42.60 on Friday. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a market cap of $2.70 billion, a P/E ratio of -16.32 and a beta of 1.08. The company has a 50-day moving average price of $45.27 and a 200 day moving average price of $40.49. Vera Therapeutics, Inc. has a 12-month low of $14.20 and a 12-month high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Institutional Investors Weigh In On Vera Therapeutics

Institutional investors have recently made changes to their positions in the stock. Samlyn Capital LLC boosted its holdings in Vera Therapeutics by 90.8% during the 2nd quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after acquiring an additional 586,410 shares during the period. First Light Asset Management LLC boosted its holdings in Vera Therapeutics by 130.6% in the second quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock valued at $36,387,000 after purchasing an additional 569,590 shares during the period. American Century Companies Inc. purchased a new position in Vera Therapeutics in the second quarter valued at $14,015,000. Logos Global Management LP increased its holdings in Vera Therapeutics by 65.2% during the 2nd quarter. Logos Global Management LP now owns 950,000 shares of the company’s stock worth $34,371,000 after purchasing an additional 375,000 shares during the period. Finally, Federated Hermes Inc. purchased a new position in shares of Vera Therapeutics in the 2nd quarter valued at about $10,492,000. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on VERA. Guggenheim raised their price objective on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Monday, October 28th. JPMorgan Chase & Co. increased their target price on Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Wells Fargo & Company began coverage on shares of Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a report on Tuesday, October 1st. Finally, Wedbush increased their target price on Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $59.22.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.